Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer
Credit: © European Society for Medical Oncology Munich, Germany, 21 October 2018 - Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor,...










